Categories: Marketing

Felpreva®, Vetoquinol’s New 3-Every month Feline Parasiticide, Gets Marketing Authorisation from the European Fee

[ad_1]

PARIS–(Business enterprise WIRE)–Vetoquinol (Paris: VETO) is delighted to announce that, pursuing optimistic belief from the Committee for Medicinal Merchandise for Veterinary Use (CVMP), the European Fee has granted advertising and marketing authorisation for Felpreva® (tigolaner/emodepside/praziquantel) for place-on avoidance and procedure of blended parasitic infestations/infections in cats.1

Felpreva® is the to start with place-on parasiticide for cats that addresses tapeworms in addition to other endoparasites which include gastrointestinal roundworms and lungworms, and ectoparasites (fleas, ticks and mites) for up to three months with a solitary dose. It is licensed for therapy of cats with, or at possibility from, blended parasitic infestations/bacterial infections, which includes:

Endoparasites:

– Gastrointestinal roundworms: infection with Toxocara cati, Toxascaris leonina and Ancylostoma tubaeforme

– Lungworms: infection with Aelurostrongylus abstrusus and Troglostrongylus brevior

– Tapeworms: infection with Dipylidium caninum and Taenia taeniaeformis

Ectoparasites:

– Flea (Ctenocephalides felis), tick (Ixodes ricinus, Ixodes holocyclus) and mite (Otodectes cynotis) infestations, as effectively as mild to reasonable cases of notoedric mange (triggered by Notoedres cati). It can also form element of a therapy tactic for flea allergic dermatitis (Fad).

Matthieu Frechin, Vetoquinol CEO, commented: “Marketing authorisation is a pivotal accomplishment for each Vetoquinol and Felpreva®. It is a breakthrough remedy with advantage and simplicity of use blended with long-lasting efficacy. We think that Felpreva® will be a real activity changer for this location of veterinary medication, demonstrating our determination to the parasiticide marketplace.”

Felpreva® is element of the endectocide course of veterinary parasiticides that addresses each interior (endo) and external (ecto) parasites. It is a combination of lively substances emodepside and praziquantel, with tigolaner, a novel energetic component.1

It is approximated that parasiticides make up the most significant segment in the companion animal veterinary pharmaceutical industry around the globe. Also, the speedy-developing endectocide classification is approximated to…

[ad_2]

Browse a lot more listed here

Jasmine Andrade

Share
Published by
Jasmine Andrade

Recent Posts

The Overlooked Step That Can Save Thousands During Construction

When people discuss rising construction costs, the conversation usually focuses on labour shortages, material prices,…

1 month ago

Pastor Dino Rizzo’s Advice for Reaching the Community Through Holiday Outreach

The holiday season brings moments of celebration, but it can also place added strain on…

6 months ago

Top 10 Mistakes to Avoid When Hiring Movers for Your Next Move

Moving to a new home or office carries excitement along with several challenges. Selecting suitable…

1 year ago

Chasen Nevett’s Visionary Investments in Capital Markets

In the dynamic landscape of global finance, Chasen Nevett has emerged as a prominent figure,…

1 year ago

How to Choose the Right Parasite Treatment for Your Dog

Protecting your dog from parasites is one of the most important responsibilities of being a…

2 years ago

Top 10 Pharmacy Trends Revolutionizing Healthcare in 2024

Pharmacy plays a crucial role in the ever-evolving healthcare landscape. In 2024, a combination of…

2 years ago